BiotechTube

Dex 21-P + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Ulcerative Colitis

Conditions

Ulcerative Colitis

Trial Timeline

Jul 22, 2003 → May 15, 2007

NCT ID
NCT01171807

About Dex 21-P + Placebo

Dex 21-P + Placebo is a phase 2 stage product being developed by Quince Therapeutics for Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01171807. Target conditions include Ulcerative Colitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01171807Phase 2Completed

Competing Products

20 competing products in Ulcerative Colitis

See all competitors
ProductCompanyStageHype Score
Mirikizumab SC + Mirikizumab IV + Placebo SCEli LillyPhase 3
77
MirikizumabEli LillyPhase 2
52
Azathioprine + PlaceboCelltrionApproved
85
CT-P13 SC (Infliximab)CelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
TacrolimusAstellas PharmaPhase 3
77
tacrolimus + PlaceboAstellas PharmaPhase 3
77
Filgotinib MaleateEisaiApproved
85
AJM300 + PlaceboEisaiPhase 3
77
GSK3050002 + PlaceboEisaiPhase 1
33
adalimumab + placeboEisaiPhase 3
77
E6007 + PlaceboEisaiPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 2
52
KHK4083 + PlaceboKyowa KirinPhase 1
33
Arm1 + Arm 2Zydus LifesciencesPhase 2
52
Mirikizumab + MirikizumabEli LillyPhase 3
77
Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SCEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 2
52
Mirikizumab + PlaceboEli LillyPhase 2
52
LY4268989 + PlaceboEli LillyPhase 2
52

Other Products from Quince Therapeutics

DexamethasonePhase 3
69
EryDex Low dose DSP + EryDex High dose DSP + Pooled PlaceboPhase 3
69
Dexamethasone sodium phosphatePhase 3
69
Dexamethasone sodium phosphatePhase 3
69
DexamethasonePhase 2
44